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A B S T R A C T
Protein storage and transport is essential to deliver therapies (biologics), enzymes for biotechnological appli-
cations, and underpins fundamental structural and molecular biology. To enable proteins to be stored and
transported it is often essential to freeze them, requiring cryoprotectants such as glycerol or trehalose. Here we
explore the mechanisms by which poly(vinyl alcohol), PVA, a potent ice recrystallisation inhibitor protects
proteins during freeze/thaw to enable solvent-free cryopreservation with a focus on comparing mixing, verses
polymer-protein conjugation. A panel of poly(vinyl alcohol)s are investigated including commercial, well-de-
fined (from RAFT), and PVA-protein conjugates, to map out PVA’s efficacy. Enzymatic activity recovery of
lactate dehydrogenase was found to correlate with post-thaw aggregation state (less aggregated protein had
greater activity), which was modulated by PVA’s ice recrystallisation inhibition activity. This macromolecular
cryoprotectant matched the performance of glycerol, but at lower additive concentrations (as low as
1 mg.mL−1). It was also demonstrated that storage at −20 °C, rather than −80 °C was possible using PVA as a
cryoprotectant, which is not possible with glycerol storage. A second protein, green-fluorescent protein (GFP),
was used to enable screening of molecular weight effects and to obtain PVA-GFP bioconjugates. It was observed
that covalent attachment of RAFT-derived PVA showed superior cryoprotectant activity compared to simple
mixing of the polymer and protein. These results show that PVA is a real alternative to solvent-based protein
storage with potential in biotechnology, food and therapeutics. PVA is already approved for many biomedical
applications, is low cost and available on a large scale, making it an ideal cryoprotectant formulation enhancer.
1. Introduction
Proteins are essential in fields ranging from biocatalysts for drug
development/discovery [1], to emerging therapies (e.g. therapeutic
antibodies [2,3], and in food technology [4]. The study of protein
function underpins structural [5,6] and chemical biology. For example,
the biologics market (which includes cell and protein therapies) is es-
timated at $250B/year and is transforming areas such as oncology
[7,8]. In all cases the protein of interest must be stabilised to ensure it
reaches the patient (or point of use) intact and functional, for both
therapeutic and economic reasons. Environmental factors such as heat,
sunlight and chemical stressors can all lead to denaturation and hence
loss of function, meaning freezing is essential to enable storage and
remove the need for continuous production. The protein cold chain
typically involves either lyophilization or freezing, both of which cause
significant stress on the proteins during the cooling cycle by related but
distinct mechanisms [9]. For example, there are pH shifts due to se-
lective crystallisation of buffer salts [10–14], and an increased ice-
water interface [15,16]. Antibodies often aggregate during freeze/thaw
cycles and have dramatically altered physicochemical properties [17]
and their actual stability varies between each antibody [18] meaning
bespoke formulations are required, adding to the final cost. In vaccines
the adjuvants are known to lower their freeze-thaw stability preventing
long term storage [19] and necessitating a complex supply chain. For
example the human papilloma virus (HPV) vaccine [20] contains alu-
minium salt adjuvants.
Proteins can degrade by three core mechanisms during storage and
transport. i) Chemical damage, such as oxidation or reaction with
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excipients; ii) Unfolding (denaturing); iii) Irreversible aggregation. (i)
Is effectively managed by careful storage conditions, but factors (ii) and
(iii) need addressing. Current solutions for protein stabilization are the
addition of osmolytes such as trehalose [21,22] or polymer formula-
tions [23] which can replace surface water molecules and make un-
folding thermodynamically unfavorable. In research laboratories gly-
cerol is widely used as a cryoprotectant for proteins, as it is simple to
add and mix (pipetted as it is a liquid) but it does not give full recovery
of function, is viscous and interferes with down-stream assays [24–27].
To address the process of irreversible protein aggregation during
storage, Tibbitt and coworkers have encapsulated enzymes into a
photo-reversible hydrogel format. This prevents protein-protein con-
tact, and hence aggregation, and it was shown that they retain their
function at ambient temperatures, by preventing this mode of dena-
turation whilst retaining hydration [28]. Kaplan and coworkers have
engineered silk proteins which can retain the activity of enzymes which
were dried together as films, and stored for up to 10 months at 37 °C
[29]. Similar technology also enabled whole blood storage for diag-
nostic samples [30]. Maynard has developed trehalose side-chain
polymers for protein protection during lyophilization. A range of tre-
halose-polymers (poly(4,6-O-(4-vinylbenzylidene)-α,α-trehalose),
polymers of α,α-trehalose modified with a styrenyl acetal, methacrylate
acetal, styrenyl ether, or a methacrylate, and poly(5,6‐benzo‐2‐methy-
lene‐1,3‐dioxepane (BMDO)‐co ‐butyl methacrylate‐trehalose)) have
been synthesized and shown to be very potent stabilizers when applied
as polymer-protein conjugates [31–33]. However, the conjugation
process itself does result in loss of activity relative to the free protein
alone, so the benefit of free polymer at higher concentrations, verses
conjugated at lower must be considered, and any new polymer requires
safety and approval processes for biomedical applications.
During the freezing of proteins, ice crystals form and exclude all
other solutes (as ice forms a pure phase) meaning the concentration of
all the solutes effectively increases, known as cryo-concentration [34].
Furthermore, as the ice crystals grow (recrystallisation) the effective
surface area (i.e. interfaces where proteins are located) decreases,
meaning that protein-protein contacts increase and hence aggregation
is more likely. In Nature ice recrystallisation is prevented by the pro-
duction of antifreeze proteins [35] which are potent ice recrystallisa-
tion inhibitors (IRIs) and can function at sub 1 mg.mL−1 concentrations
[36]. However, antifreeze proteins are not ideal for many biotechno-
logical applications, not least due to their cost compared to current
technologies such as glycerol. Therefore there is significant interest in
developing polymer mimics of antifreeze proteins, which has been ex-
tensively reviewed [37–39] as well as small molecule inhibitors [40].
The most potent IRI polymer is poly(vinyl alcohol) which is syntheti-
cally scalable, low cost, has a well-established toxicity profile and is
approved for several formulation and food based applications [41]. Due
to its high IRI activity PVA has been widely explored [42–45], including
for cell storage applications [25,46]. It should be noted that PVA’s ex-
ceptional activity is still the subject of extensive research [47], and that
IRI is a very rare property in polymers. Gibson and co-workers have
shown that PVA can be used for the solvent-free cryopreservation of
enzymes when used in combination with poly(ethylene glycol) and can
match the performance of trehalose or glycerol based methods [48].
The exact mechanism and limitations of the use of polymers as ice-
controlling excipients as a next-generation tool for the storage of pro-
teins has not yet been fully explored.
Considering the above, this work explores the use of PVA for
cryopreserving proteins both as an additive and as a covalent polymer/
protein conjugate. Firstly, the enzyme LDH, which is challenging to
cryopreserve by conventional methods, is shown to be protected by
PVA across a range of conditions. The mechanism of action is linked to
preventing the formation of protein aggregates. Secondly, a higher-
throughput assay is established using green fluorescent protein, and a
panel of well-defined PVA’s (from RAFT) were screened for activity.
Finally, PVA-GFP conjugates were synthesized and shown to lead to
protection even across many freeze/thaw cycles. This conclusively
shows that IRI active polymers have significant potential for protein-
based storage applications.
2. Results and discussion
Lactate dehydrogenase (LDH) is a challenging enzyme to cryopre-
serve (and biotechnologically important) [49,50] and was hence chosen
as the protein of interest here to explore the use of PVA’s ice re-








































































Fig. 1. LDH cryopreservation screening. A) Assay to determine LDH activity.
Reduction of NADH to NAD+ with corresponding decrease in absorbance at
340 nm; B) Activity retention (or loss) of LDH after the indicated number of
freeze/thaw cycles; C) Impact of glycerol concentration on recovery after a
single freeze/thaw cycle. [Glycerol] reported as % v/v. Freeze/thaw cycles
were Liq. N2/37 °C.
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Fig. 1A shows the assay for measuring LDH activity post-thaw; the
conversion of pyruvate to lactate, with corresponding oxidation of ni-
cotinamide adenine dinucleotide (NADH) to NAD+, which is measured
by monitoring the decrease in absorbance at 340 nm. This reaction is
rapid and hence low (0.031 nM) concentration of LDH in the final assay
are required to enable comparison of the rate of reaction. Control ex-
periments where LHD was exposed to up to 13 freeze/thaw cycles are
shown in Fig. 1B. Freeze/thaw with the addition of a range of glycerol
concentrations are shown in Fig. 1B and 1C to establish a control. As
would be expected, addition of no cryoprotectant leads to loss of ac-
tivity upon thawing and there is a non-linear relationship between
glycerol concentration and cryoprotectant outcome. The initial slope of
the curve is used for comparison from this point on.
The primary aim here was to explore how IRI active polymers
modulate protein recovery by controlling ice crystal growth. Fig. 2A
shows example ice wafers which have been grown with added PVA or
PEG (negative control with no IRI36) to highlight the unique IRI activity
of PVA. In brief, small ice crystals after annealing at sub-zero tem-
peratures indicates more IRI activity. Full dose-dependent profiles have
been previously reported and are not repeated here [36,44]. Typically
PVA inhibits all growth below 1 mg.mL−1 unless very low
(<500 g.mol−1) molecular weights are used [44,51].
The impact of IRI active/inactive polymers on freeze/thaw recovery
of LDH was evaluated, Fig. 2B/C. 100 mg.mL−1 PEG (~10 wt%, red)
showed some cryoprotective benefit. At this high concentration most
additives would have an impact and this concentration of PEG has been
previously reported for LDH cryopreservation [49]. PVA, in contrast, at
just 1 mg.mL−1 (0.1 wt%, green) gave the same recovery as 25 wt%
glycerol or 100 mg.mL−1 PEG, highlighting its potency. Increasing to
seven freeze/thaw cycles showed that glycerol performed worse than
all the polymer formulations under these conditions Figure S1). One
possible explanation for glycerol’s poorer performance under repeated
cycles is that the protein is in contact with the solution of cryoprotec-
tant at raised temperatures, which may lead to denaturation, even if it
is also protecting against cold stress. Previous reports of using IRI active
polymers for protein storage [48] found that for some proteins an ad-
ditional hydrophilic polymer was required to achieve protection, but
Fig. 2. A) Chemical structure of PEG/PVA and representative ice wafers grown
with each polymer [PEG] = 10 mg.mL−1, [PVA] = 1 mg.mL−1; B) LDH ac-
tivity recovery in the (PEG = 100 mg.mL−1, PVA = 1 mg.mL−1) after 5 FT
cycles (−196 to 25 °C), recorded by catalysis of NADH to NAD+, observed by a
decrease in absorbance, compared to a no CPA control (buffer); C) Zoom in of
linear region.








































Fig. 3. Variable storage period analysis. All samples were plunge frozen into Liq. N2, stored at −20 °C for indicated period of time and then thawed at 37 °C. A) 24 h;
B) 7 days; C) 1 month. PEG = 100 mg.mL−1, PVA = 1 mg.mL−1.
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the observations made here suggest the exact formulations needed for
practical storage may vary between proteins and that a minimal solu-
tion of just PVA may be sufficient for some, which is desirable.
The above data shows that IRI active polymers can be employed to
prevent freeze/thaw induced deactivation of LDH. However, it is im-
portant to comment that the experiments were conducted under con-
ditions that are impractical and not truly representative of routine use
in a laboratory. Therefore, we set out to look at the impact of storing the
proteins at −20 °C (i.e. the temperature of a standard laboratory
freezer) for 1 day to 1 month, as a truly rigorous test of the utility of this
technology, and to show the potential for reducing the need for energy
intensive −80 °C freezers, Fig. 3. The samples were prepared as above
and plunged into Liq. N2 then transferred to the −20 °C freezer. Note,
this was crucial to ensure the samples freeze, and to avoid unfair
comparisons (glycerol solutions would take a long time to freeze di-
rectly in −20 °C and we did not want to bias cryopreservation results
due to protein denaturation due to extended contact with liquid gly-
cerol). After 24 h storage and thawing, all samples performed well with
some retention of activity – notably, even the PBS control gave some
protection (thus highlighting that proteins themselves can survive some
cold stress intrinsically). After 7 days storage at − 20 °C glycerol
continued to perform well but the PEG/PVA mixtures began to lose
activity, which upon 28 days storage performed poorly. All other for-
mulations retained some activity at 28 days, and interestingly the PVA
at just 1 mg.mL−1 (~0.1 wt%) successfully protected the LDH, giving
the same results as PEG at 100 × higher concentration. This analysis
shows that PVA is indeed a potent protein cryoprotectant, which
functions at concentrations far lower than other polymers or indeed the
current standard of glycerol, but that some additional formulation may
be required for an individual protein sample, to achieve optimum re-
sults.
To validate the hypothesis that irreversible protein aggregation was
a primary mechanism for loss of enzyme activity, dynamic light scat-
tering (DLS) was used. If PVA is inhibiting ice growth, and hence re-
ducing the effective protein concentration at ice crystal surfaces, then
there will be less protein aggregation (due to fewer protein-protein
contacts). Hence as DLS is sensitive to size (hydrodynamic diameter)
this effect can be probed. Fig. 4A shows that before freezing only par-
ticles (protein) below 10 nm were observed, but after freeze/thaw the
diameters dramatically increased to>1000 nm. This correlates well
with the LDH enzymatic activity data. In contrast to LDH in buffer, a
solution of LDH with just 1 mg.mL−1 PVA showed essentially no ag-
gregation over 7 freeze/thaw cycles and confirms that aggregation
prevention is the (or at least part of) the mechanism of cryoprotection
by IRI active polymers, Fig. 4B. [Note, the exact size/distribution in
Fig. 4B shows some variance in diameter and intensity as samples were
withdrawn from a master batch to take DLS (rather than the same vial
being freeze/thawed), which leads to some variability, but still de-
monstrates the principle.] The observations made here are significant as
many protein-based pharmaceuticals cannot be frozen due to aggrega-
tion, including insulin, which can form amyloid – like aggregates [52]
and vaccines, which cannot be stored frozen [19]. It should be noted,
that there are previous reports showing that slow freezing of proteins
(to encourage larger crystals) performed better than fast freezing (to
produce smaller crystals). The hypothesis was that reducing protein
contact with the ice surface is preferential [50]. This is in contrast to
our results, although the same work did note that recrystallisation upon
thawing was a problem, which our polymers also mitigate. Hence the
benefits seen here could be associated with balancing the different
denaturation pathways.
The above data demonstrated that IRI active polymers protect LDH
from freeze-induced damage by preventing irreversible aggregation.
There does remain, however, the question of if the polymer in solution
is required, or if covalent conjugation of the polymer to the protein
gives the most protection, by effectively concentrating the polymer at
the protein surface? Answering this may also bring understanding into
the underpinning mechanism of protection. PVA itself is appealing for
this application due to its widespread use in formulations and low cost.
To enable us to probe if PVA–protein conjugates are cryo-stable, and to
gain more detail about how the absolute magnitude of IRI activity of the
polymers can impact the cryopreservation outcomes, an alternative
protein was used which also enabled more high-throughput testing.
Green fluorescent protein (GFP) was selected as the probe, and was
produced by recombinant expression in E. coli. GFP Fluoresces (ex-
citation at 395 nm, emission at 509 nm) when correctly folded, and
upon denaturation the fluorescence intensity decreases. It is important,
however, to note that GFP is itself relatively freeze tolerant, so multiple
cycles (below) are used. We have previously reported that PVA used in
combination with PEG can protect GFP [48] using commercial PVA. For
the polymer-protein conjugation studies conducted here PVA will be
the only additive (as the covalent conjugate), so it was first essential to
Fig. 4. Dynamic light scattering analysis of freeze/thaw induced aggregation of
LDH and impact of PVA. A) LDH size distribution over 7 freeze/thaw cycles
with (right) and without (left) PVA; B) LDH size distribution over 7 freeze/thaw
cycles. [PVA] = 1 mg.mL−1 (Freeze/Thaw cycle was Liq. N2/25 °C).
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study the role of PVA as the sole additive without conjugation, to es-
tablish a baseline.
For this part of the study, a panel of PVA’s were synthesised using
RAFT (Reversible Addition-Fragmentation Chain Transfer) poly-
merization, Table 1. Vinyl acetate was polymerised using 2-(ethox-
ycarbonothioyl)sulfanyl propanoate (EXEP) in bulk. Conversion was
determined by 1H NMR, and the higher [M]:[CTA] resulted in lower
conversions, as would be expected for lesser activated monomers (LAM)
in bulk polymerisation. SEC of the PVAc’s revealed monomodal dis-
tributions, but broader than would be expected for normal RAFT, due to
the nature of VAc as a LAM. The acetate groups were quantitatively
removed by hydrazine to generate PVA, as confirmed by IR and 1H
NMR spectroscopy, Fig. 5.
To evaluate the cryoprotective properties of the PVA, GFP was
prepared in PBS at 1 µM and a dilution series of each polymer added.
The solutions were frozen to −20 °C, and then allowed to thaw at room
temperature. After each freeze/thaw cycle, fluorescence was measured
at excitation of 395 nm, emission at 509 nm and reported relative to the
starting fluorescence. It is crucial to note that this method enabled
testing of the same sample after each cycle, whereas an enzymatic assay
would require removal of some sample, or using a very large number of
individual replicates, and hence this GFP method enabled screening.
The data is reported in Fig. 6. Without any polymer additives, GFP
alone loses its fluorescence and after 6 cycles it has fallen to below 50%
of its starting value.
The data in Fig. 6 confirmed that PVA can mitigate the damage to
GFP upon freeze-stress and that there is a dose-dependency to its
function with excess PVA being detrimental. Bell shaped responses to
antifreeze protein (or PVA) concentration in cellular cryopreservation
has been reported [46,53,54] due to needle–like ice crystals damaging
cell membranes, but this seems unlikely to be a problem for protein
storage. There was no clear molecular weight dependency but it ap-
peared the shorter polymers may have some benefit compared to
longer. This could be due to aggregation of the PVA itself, as higher
molecular weights are known to form gel particles during freeze/thaw
cycling [55,56]. It is important to note that here PEG was not added as a
secondary cryoprotectant, unlike in previous reports of IRI-driven
protein stabilisation where the secondary non–IRI active polymer en-
hanced its function [48]. This experimental condition was essential to
enable evaluation of the role of PVA, rather than to obtain the ‘best’
system and to guide parameters for the polymer-protein conjugation
(below) where only a single polymer would be added. The data does
confirm that PVA has a beneficial effect and that the formulation of the
PVA conditions are essential to each protein used, but that in general
lower molecular weights are preferred, below 10 kg.mol−1 [48].
From the above we cannot rule out any other roles of the polymer in
stabilising, e.g. through hydrophobic contacts. Maynard has shown that
trehalose-functional polymers can protect various proteins during
freeze stress when covalent conjugated to proteins, and their efficacy is
reduced when added free in solution [31,32]. Therefore, a strategy was
devised to conjugate PVA to GFP. It should be noted that conjugation of
PVA is extremely challenging as it must be obtained from a precursor
polymer (PVAc) and the acetate groups removed (under basic condi-
tions). There is only a single previous report of PVA-protein conjugation
Table 1
Poly(vinyl alcohol)/poly(vinyl acetate)s synthesised here.
PVAc Code [M]:[I] Conversion(a) (%) MnTheo(b) (g.mol−1) MnSEC(c) (g.mol−1) ĐSEC(c) PVA Code
PVAc 21 25:1 82 1800 2000 1.34 PVA 21
PVAc 71 100:1 80 6900 6400 1.40 PVA 71
PVAc 100 125:1 71 7600 8800 1.61 PVA 100
PVAc 148 200:1 63 8000 13,000 1.66 PVA 148
PVAc 183 250:1 54 11,600 16,000 1.63 PVA 183
PVAc 294 1000:1 32 27,500 25,600 1.80 PVA 294































Fig. 5. Synthesis and characterization of PVAc/PVA. A) RAFT/MADIX poly-
merization of vinyl acetate, followed by deacetylation; B) 1H NMR analysis
showing removal of acetate protecting group * residual DMSO, + residual
HOD; C) FTIR of before/after acetate removal.
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using commercial disperse PVA [57].
To generate a PVA which could be conjugated via a chain end
RAFT/MADIX was employed (as above), but deprotection was achieved
using NaOH to generate a carboxylic acid end-group from the terminal
carboxylic acid ester (as opposed to hydrazide when hydrazine is used).
Two model polymers were prepared as shown in Table 2. These poly-
mers were conjugated to GFP using EDC/NHS coupling for targeting of
surface lysine residues by adding a large excess of the polymer, Fig. 7A.
After conducting the conjugation reaction in pH 6 phosphate buffer for
12 h, purification was achieved using FPLC (fast protein liquid chro-
matography), Fig. 7B. GFP in solution always forms some aggregates
which can be seen at 20 mL. After conjugation a shift to shorter elution
times, consistent with an increase in molecular weight was observed,
and the indicated fractions were collected. By using UV/Vis spectro-
scopy to measure (at 280 nm) the protein concentration in a known
weight of purified conjugate, the average number of PVA chains at-
tached to each GFP was determined to be 15 for GFP-PVA32 and 11 for
GFP-PVA121. These were then assayed for freeze/thaw protection as
described above. Importantly the conjugation process did itself not lead
to any reduction in fluorescence compared to (lyophilized) protein
alone (Figure S3. Initial loss of fluorescence after the first thaw was
observed for the conjugates and the GFP control, and the PVA32 GFP
mixture, but not with PVA121 GFP Fig. 7C. Subsequent freeze/thaw
cycles showed that the fluorescence activity of the conjugates was es-
sentially unaffected after the initial loss, compared to the PVA GFP
mixtures and the GFP control which consistently lost activity with each
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Fig. 6. Fluorescence intensity at ex/em 395/509 nm for various PVA polymers at different concentrations, reported at percentages of initial recorded fluorescence; A)
PVA21; B) PVA71; C) PVA100; D) PVA148; E) PVA183; F) PVA294.
Table 2
Poly(vinyl acetate)/Poly(vinyl alcohol) synthesised for bioconjugation.
PVAc Code [M]:[I] Conversion (%) MnTheo (g.mol−1) MnSEC (g.mol−1) ĐGPC PVA Code
PVAc 32* 30:1 90 2300 2760 1.31 PVA 32*
PVAc121* 150:1 76 9800 10,500 1.48 PVA 121*
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cycle and after 5 cycles dropped to 40% of the initial fluorescence. After
extended testing of 15 cycles, GFP-PVA conjugates retained fluores-
cence output with no further loss of activity, whilst GFP-alone had es-
sentially lost all almost activity (6% of initial fluorescence) and the
PVA-GFP mixtures had dropped to similar levels.
This data shows that covalent conjugation of PVA is a potent tool for
protein cryoprotection. This beneficial effect might be due to localisa-
tion, whereby the polymers are present at high concentration on the
protein surface and locally controlling ice growth, or a combination of
this and general stabilisation against unfolding and aggregation due to
the steric bulk of conjugated polymer. PVA is also appealing due to its
low cost and known safety profile unlike bespoke new polymers, and
hence this approach may be suitable for application to freeze-sensitive
proteins, especially as the conjugation method is straightforward and
does not require site-specific modification.
3. Conclusions
Herein we report a detailed study on the use of poly(vinyl alcohol),
PVA, as a cryoprotectant for protein storage based on its potent ice
recrystallisation inhibition (IRI) activity. Its ability to cryopreserve two
different proteins (lactate dehydrogenase and green fluorescent pro-
tein) as both an additive and as a covalent polymer/protein conjugate is
demonstrated. Using lactate dehydrogenase, PVA was shown to enable
cryopreservation at just 1 mg.mL−1, matching, or out-performing gly-
cerol, which required significantly higher concentrations to protect the
protein. Activity was retained even through multiple freeze/thaw cy-
cles, or storage at −20 °C, which is relevant for routine laboratory
usage. It is shown that LDH recovery correlated with the inhibition of
irreversible aggregation, supporting the hypothesis that ice re-
crystallisation drives protein aggregation during cryostorage. To further
probe this, a high-throughput assay using green-fluorescent protein as
the read-out was employed to screen the impact of PVA molecular
weight on cryopreservation. Using a panel of PVA’s derived from RAFT/
MADIX it was seen that all PVAs can provide some protection but that
the strong molecular weight dependent trends observed with the IRI
activity of PVA were not present here, and that all molecular weights
performed similarly, with PVA concentration being main factor. Finally,
a strategy was devised to enable non-specific PVA conjugation to GFP
using RAFT polymerization. The polymer-protein conjugate was more
stable to freeze/thaw stress than protein with the same amount of non-
conjugated PVA, with no appreciable loss or change in protein activity
even after fifteen freeze thaw cycles. These results show that the
structurally simple, low cost and widely – used polymer PVA is indeed a
potent macromolecular cryoprotectant for proteins. This may help de-
sign innovative storage formulations across a range of application areas
from vaccines to biocatalysts.
4. Experimental section
4.1. Materials
All chemicals were used as supplied. Ethyl acetate, hexane, me-
thanol, Petroleum ether 40–60 °C dichloromethane and magnesium
sulphate were all purchased from Fisher Scientific at laboratory reagent
grade. Deuterated chloroform (99.8 atom %D), dimethyl sulfoxide-d6
(99.9 atom %D), vinyl acetate (97.0%), 4,4′-azo-bis(4-cyanovaleric
acid) (≥80.0%), 2,2′-azo-bis(2-methylpropionitrile) (98%), potassium
ethyl xanthate (96%), 2-(methyl bromopropionate) (98%), aqueous
hydrazine hydrate solution (50–60%), PBS buffer (preformulated ta-
blets, yielding 0.01 M phosphate buffer, 0.0027 M potassium chloride
and 0.137 M sodium chloride, pH 7.4), N-Ethyl-N′-(3-dimethylamino-
propyl)carbodiimide hydrochloride (EDC.HCl,> 99.0%), N-hydroxy
succinimide (NHS, 98%), imidazole (> 99%), β-nicotinamide adenine
dinucleotide, reduced disodium salt hydrate (NADH 97%), sodium
pyruvate (ReagentPlus > 99%), polyethylene glycol (BioUltra 4000),
poly(vinyl alcohol) (MW 9–10 kDa, 80% hydrolysed) and SealPlate
films were purchased from Sigma Aldrich. L–lactate dehydrogenase was
purchased from Roche. MilliQ water (18.2 mΩ).
Protein expression and purification are described in the Supporting
Information.
4.2. Physical and analytical methods
Ice recrystallisation inhibition (‘splat’) assay is described in the



















































Fig. 7. PVA-GFP bioconjugation and freeze/thaw tolerance. A) Synthetic
strategy for conjugation of PVA to GFP via EDC/NHS coupling; B) FPLC proof of
conjugation and indicated fractions used for purification; C) % Fluorescence
recovery of GPF fluorescence after freeze/thaw cycles for GFP, PVA conjugated,
and PVA mixed (non-conjugated). [PVA] = 0.2 mg.mL−1.




1H and 13C NMR spectra were recorded at 400 MHz on a Bruker DPX
– 400 spectrometer respectively, using deuterated solvents purchased
from Sigma Aldrich. Chemical shifts of protons are reported as δ in parts
per million (ppm) and are relative to tetramethylsilane (TMS) at
δ = 0 ppm when using DMSO or solvent residual peak (CH3OH,
δ = 3.31 ppm/ DMSO, δ = 2.50 ppm/ D2O, δ = 4.79 ppm).
4.2.2. Size exclusion chromatography
Size exclusion chromatography (SEC) analysis was performed on an
Agilent Infinity II MDS instrument equipped with differential refractive
index (DRI), viscometry (VS), dual angle light scatter (LS) and variable
wavelength UV detectors. The system was equipped with 2x PLgel
Mixed C columns (300 × 7.5 mm) and a PLgel 5 µm guard column. The
eluent is CHCl3 with 2% TEA (triethylamine). Samples were run at
1 mL/min at 30 °C. Poly(methyl methacrylate), and polystyrene stan-
dards (Agilent EasyVials) were used for calibration. Analyte samples
were filtered through a GVHP membrane with 0.22 μm pore size before
injection. Respectively, experimental molar mass (Mn, SEC) and dis-
persity (Đ) values of synthesized polymers were determined by con-
ventional calibration using Agilent GPC/SEC software.
4.3. Protein assays
4.3.1. LDH freeze/thaw assay
NADH and sodium pyruvate were made up to stock concentrations
of 63 mM and 10 mM respectively. NADH (4 µL) and sodium pyruvate
(10 µL) were added to 1 mL PBS to make the reaction buffer. All po-
tential cryoprotectants (glycerol, 4 kDa PEG, 10 kDa PVA, PEG/PVA)
were added to LDH in a 50:50 vol and frozen in triplicate at the chosen
temperature (−196 °C or −20 °C). The samples were thawed at 25 °C
after ≥1 cycles. 5 µL of CPA:LDH samples were added to a 96 well plate
and diluted by the addition of the reaction buffer (195 µL) to give a
final protein concentration of 0.031 nM. This concentration was es-
sential to allow the rate of reaction to be observed due to the rapid
kinetics of this enzyme. Absorbance at 340 nm was recorded over
30 min at 25 °C using a BioTek Synergy HTX multimode reader and
compared to that of an unfrozen LDH control and unreacted NADH.
4.3.2. GFP freeze/thaw assay
PVA and GFP was made up to a stock concentrations of 11 mg.mL−1
and 30 µg.mL−1 respectively in PBS buffer (0.1 M, pH 7.4). PVA stock
solution was added in serial dilution (180 µL) to a black 96 well plate in
triplicate. GFP (20 µL) was then added to each well and the plate sealed
with SealPlate film. Fluorescence was recorded at 25 °C using a BioTek
Synergy HTX multimode reader using an excitation wavelength of
395 nm and an emission wavelength of 509 nm. Samples were then
frozen at −20 °C and then thawed at ambient temperature. The
fluorescence recorded as above as compared to that of the unfrozen GFP
PVA solutions.
4.4. Synthetic methods
PVA and PVAc would synthesized according to previously reported
protocols [44], and are described fully in the Supporting Information.
4.4.1. Synthesis of PVA-GFP conjugates
As a representative example, PVA32 (0.2 g, 1400 g.mol−1, 400 eq
protein, (25 eq surface lysine)), EDC. HCl (10 mg, 8 × 10−5 mol,
400 eq protein) and N-hydroxysuccinimide (8 mg, 8 × 10−5 mol,
400 eq protein) were dissolved in phosphate buffer (pH6, 5 mL) at 4 °C
and allowed to stir for 5 min. GFP (10 mg, 0.38 mL of 1 mM stock
solution, 1 eq protein, (17 eq surface lysine)) was added and the re-
action allowed to proceed at 4 °C for 8 h. The reaction was then
concentrated by centrifugal dialysis (MWCO 10 kDa) (note: 30 kDa was
used for larger PVA conjugates). Concentrated solutions were then
purified using FPLC in PBS buffer (0.1 M, pH 7.4) by collecting the
fractions relating to PVA-GFP conjugate. Conjugates were characterised
by a combination of FPLC and UV/Vis spectroscopy of the dialysed and
freeze-dried sample, to calculate the protein concentration in the
overall mass of the conjugate to determine degree of conjugation.
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